Association of endothelial dysfunction and no-reflow during primary percutaneous coronary intervention for ST-elevation myocardial infarction

Cardiovascular Revascularization Medicine

Volumn 17, Issue 8, 2016, Pages 552-555

  Levi, Yaniv ^a,b   Sultan, Ayyaz ^a,b   Alemayehu, Mistre ^b   Wall, Sabrina ^b   Lavi, Shahar ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Acute MI; Angiography; No reflow

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MIDDLE AGED; NO REFLOW PHENOMENON; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SMOKING; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; AGED; BLOOD FLOW; CASE CONTROL STUDY; HEART STROKE VOLUME; HYPEREMIA; MANOMETRY; MICROCIRCULATION; NO-REFLOW PHENOMENON; ONTARIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; UPPER LIMB; VASCULAR ENDOTHELIUM; VASCULARIZATION;

AGED; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPEREMIA; MALE; MANOMETRY; MICROCIRCULATION; MIDDLE AGED; NO-REFLOW PHENOMENON; ONTARIO; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; RISK FACTORS; ST ELEVATION MYOCARDIAL INFARCTION; STROKE VOLUME; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 84994812829     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2016.08.013     Document Type: Article

References (32)

1. [1] Andersen, HR, Nielsen, TT, Rasmussen, K, Thuesen, L, Kelbaek, H, Thayssen, P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349 (2003), 733–742.
2. [2] Keeley, EC, Boura, JA, Grines, CL, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003), 13–20.
3. [3] Sorajja, P, Gersh, BJ, Costantini, C, McLaughlin, MG, Zimetbaum, P, Cox, DA, et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005), 667–674.
4. [4] Yip, HK, Chen, MC, Chang, HW, Hang, CL, Hsieh, YK, Fang, CY, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 122 (2002), 1322–1332.
5. [5] Rezkalla, SH, Kloner, RA, Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv 72 (2008), 950–957.
6. [6] Piana, RN, Paik, GY, Moscucci, M, Cohen, DJ, Gibson, CM, Kugelmass, AD, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 89 (1994), 2514–2518.
7. [7] Resnic, FS, Wainstein, M, Lee, MK, Behrendt, D, Wainstein, RV, Ohno-Machado, L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 145 (2003), 42–46.
8. [8] Heusch, G, Schulz, R, Haude, M, Erbel, R, Coronary microembolization. J Mol Cell Cardiol 37 (2004), 23–31.
9. [9] Skyschally, A, Leineweber, K, Gres, P, Haude, M, Erbel, R, Heusch, G, Coronary microembolization. Basic Res Cardiol 101 (2006), 373–382.
10. [10] Furuichi, K, Wada, T, Iwata, Y, Kokubo, S, Hara, A, Yamahana, J, et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia–reperfusion injury. Crit Care Med 34 (2006), 2447–2455.
11. [11] Carden, DL, Granger, DN, Pathophysiology of ischaemia-reperfusion injury. J Pathol 190 (2000), 255–266.
12. [12] Quyyumi, AA, Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105 (1998), 32S–39S.
13. [13] Janssens, SP, Shimouchi, A, Quertermous, T, Bloch, DB, Bloch, KD, Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem 267 (1992), 14519–14522.
14. [14] Halcox, JP, Schenke, WH, Zalos, G, Mincemoyer, R, Prasad, A, Waclawiw, MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 (2002), 653–658.
15. [15] Heitzer, T, Schlinzig, T, Krohn, K, Meinertz, T, Munzel, T, Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001), 2673–2678.
16. [16] Lavi, S, Prasad, A, Yang, EH, Mathew, V, Simari, RD, Rihal, CS, et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 115 (2007), 2621–2627.
17. [17] Lavi, S, Bainbridge, D, D'Alfonso, S, Diamantouros, P, Syed, J, Jablonsky, G, et al. Sevoflurane in acute myocardial infarction: a pilot randomized study. Am Heart J 168 (2014), 776–783.
18. [18] Rubinshtein, R, Kuvin, JT, Soffler, M, Lennon, RJ, Lavi, S, Nelson, RE, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 31 (2010), 1142–1148.
19. [19] Bonetti, PO, Pumper, GM, Higano, ST, Holmes, DR Jr., Kuvin, JT, Lerman, A, Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 44 (2004), 2137–2141.
20. [20] Lavi, S, Thorpe, K, Luca, MC, Liuni, A, Floras, J, Horlick, EM, et al. Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial. Can J Cardiol 28 (2012), 215–221.
21. [21] Vijayalakshmi, K, Whittaker, VJ, Kunadian, B, Graham, J, Wright, RA, Hall, JA, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 92 (2006), 1278–1284.
22. [22] Hillegass, WB, Dean, NA, Liao, L, Rhinehart, RG, Myers, PR, Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 37 (2001), 1335–1343.
23. [23] Ndrepepa, G, Tiroch, K, Keta, D, Fusaro, M, Seyfarth, M, Pache, J, et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 3 (2010), 27–33.
24. [24] Niccoli, G, Lanza, GA, Spaziani, C, Altamura, L, Romagnoli, E, Leone, AM, et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 117 (2007), 306–311.
25. [25] Barua, RS, Ambrose, JA, Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol 33 (2013), 1460–1467.
26. [26] Andrikopoulos, GK, Richter, DJ, Dilaveris, PE, Pipilis, A, Zaharoulis, A, Gialafos, JE, et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the “smoker's paradox” in a countrywide study. Eur Heart J 22 (2001), 776–784.
27. [27] Gourlay, SG, Rundle, AC, Barron, HV, Smoking and mortality following acute myocardial infarction: results from the National Registry of myocardial infarction 2 (NRMI 2. Nicotine Tob Res 4 (2002), 101–107.
28. [28] Kelly, TL, Gilpin, E, Ahnve, S, Henning, H, Ross, J Jr., Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 110 (1985), 535–541.
29. [29] Molstad, P, First myocardial infarction in smokers. Eur Heart J 12 (1991), 753–759.
30. [30] Dong-bao, L, Qi, H, Zhi, L, Shan, W, Wei-ying, J, Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction. Clin Cardiol 33 (2010), E7–12.
31. [31] Taddei, S, Virdis, A, Ghiadoni, L, Sudano, I, Salvetti, A, Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 62 (2002), 265–284.
32. [32] John, S, Schneider, MP, Delles, C, Jacobi, J, Schmieder, RE, Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J, 149, 2005, 473.